Melbourne, Australia; 28 February 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP) is pleased to announce the appointment of existing nonexecutive director Dr Paul Wotton as Chairman of the Board of Directors. With Cynata now transitioning to a clinical stage company, the Board believes that Dr Wotton has the skills, focus and proven track record to help steer the Company effectively through this next stage of growth. Past chairman Dr Stewart Washer will remain on the Board as a non-executive Director. [Read more…]
Cynata Advances Development of Cymerus™ MSCs for the Treatment of Asthma
- Final report of initial preclinical study confirms Cymerus™ MSCs have significant beneficial effects on all three key components of asthma: airway hyper-responsiveness, inflammation and airway remodelling
- Additional preclinical study expected to pave the way for a potential clinical trial
Melbourne, Australia; 2 March 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has signed an agreement with the Monash Lung Biology Network, a consortia involving researchers from the Monash Biomedicine Discovery Institute and Department of Pharmacology at Monash University, Melbourne, to conduct a further preclinical study to support the use of CymerusTM mesenchymal stem cells (MSCs) for the treatment of asthma. [Read more…]
StemBioSys Licenses Additional Technology From UT Health San Antonio To Expand Existing Portfolio on Stem Cell-Enabling Technologies
SAN ANTONIO – StemBioSys Inc. announced that it has licensed additional technology from UT HealthTM San Antonio that expands the company’s intellectual property portfolio aimed at enabling the expansion of adult stem cells for therapeutic use.
To date StemBioSys has converted three pending patents originally licensed from UT HealthTM San Antonio into eight issued and a dozen pending patent applications. The latest technology is aimed at the enrichment and amplification of highly potent stem cells from elderly individuals. [Read more…]
International Stem Cell Community Day in Hamburg
Hamburg/Juelich, February 20, 2017 – On April 4, 2017 the first international Stem Cell Community Day will take place in Hamburg. Experts from academia and industry will discuss the status quo, perspectives, and challenges in stem cell cultivation for research and therapy, according to the event’s motto: “Bioprocessing Technologies in Stem Cell Research – Challenges and Chances for Commercialization” [Read more…]
Luxcel, Axiogenesis, and BMG LABTECH Secure €2.5M for Cell Metabolism Analysis Platform
Luxcel Biosciences, Axiogenesis, and BMG LABTECH have announced €2.5M in funding to develop and launch a cell metabolism analysis platform, MetaCell™.
Together, these companies European technology subject matter experts (SMEs) have been awarded €2.5m funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot. The funding will support development of a cell metabolism analysis platform that aims to become integral to in vitro cell biology and drug development. [Read more…]
- « Previous Page
- 1
- …
- 272
- 273
- 274
- 275
- 276
- …
- 340
- Next Page »